GSK terminated its 2020 licensing agreement with Ideaya Biosciences and returned two clinical programs to the California biotech. The split follows prior reductions in the collaboration and leaves Ideaya with full ownership of Werner Helicase and Pol Theta programs previously in the partnership. Ideaya’s SEC filing states the transfer will take effect after a notice period and that the company will evaluate strategic options for the returned assets in 2026. Ideaya noted the change will not materially affect its cash runway expectation through 2030. The decision underscores shifting alliance dynamics in synthetic lethality approaches and may prompt Ideaya to seek new partners or advance in‑house development toward value‑enhancing milestones.